The NIH's decision to cut funding for indirect costs, now capped at 15%, has faced backlash, including a temporary legal block by a federal judge after lawsuits from 22 states and universities. Critics argue this funding is essential for medical research infrastructure, while some support the cuts for potential reallocations to direct research costs. The ruling emphasizes the ongoing tensions surrounding federal scientific funding and its implications for U.S. medical research.